rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Perrigo Company plc

PRGO · NYSE

Health CareBiotechnologyJust started moving

PRGO stood above a rising 150-day average in 2 of the last 52 weekly readings, including each of the last 2 weeks. It is 34.5% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Just started moving
Weeks in an uptrend
2 in a row
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$106K
Insider sales, 12 months
$0
Officials’ trades on record
76

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$465K$0$372KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

76 disclosed lines: House 62, Senate 6, executive 8; 10 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k29 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k17 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k4 Jun 2026filed 22 Aug 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k15 May 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k30 Apr 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k30 Mar 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k26 Feb 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k30 Jan 2026filed 14 May 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39bought$1k–$15k18 Mar 2020filed 16 Apr 2020
Richard L. Hanna House: U.S. House ClerkNY22sold$250k–$500k5 Dec 2017filed 18 Jan 2017
Francis Rooney House: U.S. House ClerkFL19bought$1k–$15k8 Feb 2017filed 17 Feb 2017
Susan M. Collins Senate: U.S. Senate eFDSenatorboughtspouse$15k–$50k30 Dec 2016filed 10 Jan 2017

Insiders

Buy orders, 12 months1
Sale orders, 12 months0
Buyers · sellers1 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

News

No headline names it lately.

Everyone who traded it

Bradley A. Alford Company insiderDirector · last 11 Sep 20261 · 0
Geoffrey M. Parker Company insiderDirector · last 11 Sep 202610 · 0
David Ball Company insiderEVP & CBDO · last 9 Sep 20260 · 0
Donald J. Trump Executive branchWhite House Office · last 29 Jul 20263 · 5
Abigail Lennox Company insiderEVP and CSO · last 8 Jul 20261 · 0
Ahmed Salman Amin Company insiderDirector · last 8 Jul 20260 · 0
Albert Manzone Company insiderInterim President and CEO · last 8 Jul 20260 · 0
Charles Atkinson Company insiderEVP, General Counsel & Sec. · last 8 Jul 20261 · 0
Eduardo Guarita Bezerra Company insiderEVP & Chief Financial Officer · last 8 Jul 20262 · 0
Matthew John Winterman Company insiderEVP, Supply, Ops, Strategy · last 8 Jul 20260 · 0
Muhammad Omer Gajial Company insiderDirector · last 8 Jul 20260 · 0
Robert Willis Company insiderEVP & CHRO · last 8 Jul 20264 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202535.1%
Operating profit marginFY 2025 · to 31 Dec 2025-26.4%
Free cash flow marginFY 2025 · to 31 Dec 20253.4%
Return on capital employedFY 2025 · to 31 Dec 2025-14.9%
Debt to equityFY 2025 · to 31 Dec 20251.24×
Research spendFY 2025 · to 31 Dec 20252.2%
Share count trendFY 2025 · to 24 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$531.6M
Free cash flowFY 2025 · to 31 Dec 2025$145.1M

Analyst forecasts

No analyst forecasts yet.